These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27049060)

  • 1. Sphingosine-1-phosphate receptor-1 (S1P
    Karuppuchamy T; Behrens EH; González-Cabrera P; Sarkisyan G; Gima L; Boyer JD; Bamias G; Jedlicka P; Veny M; Clark D; Peach R; Scott F; Rosen H; Rivera-Nieves J
    Mucosal Immunol; 2017 Jan; 10(1):162-171. PubMed ID: 27049060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
    Scott FL; Clemons B; Brooks J; Brahmachary E; Powell R; Dedman H; Desale HG; Timony GA; Martinborough E; Rosen H; Roberts E; Boehm MF; Peach RJ
    Br J Pharmacol; 2016 Jun; 173(11):1778-92. PubMed ID: 26990079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment.
    Cheng Q; Ma S; Lin D; Mei Y; Gong H; Lei L; Chen Y; Zhao Y; Hu B; Wu Y; Yu X; Zhao L; Liu H
    Cell Mol Immunol; 2015 Nov; 12(6):681-91. PubMed ID: 25088224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
    Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
    Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine 1-Phosphate Receptor 1 Signaling Maintains Endothelial Cell Barrier Function and Protects Against Immune Complex-Induced Vascular Injury.
    Burg N; Swendeman S; Worgall S; Hla T; Salmon JE
    Arthritis Rheumatol; 2018 Nov; 70(11):1879-1889. PubMed ID: 29781582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury.
    Bajwa A; Rosin DL; Chroscicki P; Lee S; Dondeti K; Ye H; Kinsey GR; Stevens BK; Jobin K; Kenwood BM; Hoehn KL; Lynch KR; Okusa MD
    J Am Soc Nephrol; 2015 Apr; 26(4):908-25. PubMed ID: 25145931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P
    Pondelick AM; Moncayo LV; Donvito G; McLane VD; Gillespie JC; Hauser KF; Spiegel S; Lichtman AH; Sim-Selley LJ; Selley DE
    Neuropharmacology; 2024 Dec; 261():110165. PubMed ID: 39303855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3.
    Maeda Y; Matsuyuki H; Shimano K; Kataoka H; Sugahara K; Chiba K
    J Immunol; 2007 Mar; 178(6):3437-46. PubMed ID: 17339438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
    Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T
    PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes.
    Singer II; Tian M; Wickham LA; Lin J; Matheravidathu SS; Forrest MJ; Mandala S; Quackenbush EJ
    J Immunol; 2005 Dec; 175(11):7151-61. PubMed ID: 16301618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosin-1-phosphate Receptor 1: a Potential Target to Inhibit Neuroinflammation and Restore the Sphingosin-1-phosphate Metabolism.
    Kolahdooz Z; Nasoohi S; Asle-Rousta M; Ahmadiani A; Dargahi L
    Can J Neurol Sci; 2015 May; 42(3):195-202. PubMed ID: 25860537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo.
    Lan YY; De Creus A; Colvin BL; Abe M; Brinkmann V; Coates PT; Thomson AW
    Am J Transplant; 2005 Nov; 5(11):2649-59. PubMed ID: 16212624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca(2+)]i increases in renal mesangial cells.
    Koch A; Völzke A; Puff B; Blankenbach K; Meyer Zu Heringdorf D; Huwiler A; Pfeilschifter J
    Biochim Biophys Acta; 2013 Nov; 1831(11):1634-43. PubMed ID: 23906789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17-Producing Vγ4+ γδ T Cells Require Sphingosine 1-Phosphate Receptor 1 for Their Egress from the Lymph Nodes under Homeostatic and Inflammatory Conditions.
    Maeda Y; Seki N; Kataoka H; Takemoto K; Utsumi H; Fukunari A; Sugahara K; Chiba K
    J Immunol; 2015 Aug; 195(4):1408-16. PubMed ID: 26170380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P
    Stepanovska Tanturovska B; Zivkovic A; Imeri F; Homann T; Kleuser B; Stark H; Huwiler A
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
    Oo ML; Thangada S; Wu MT; Liu CH; Macdonald TL; Lynch KR; Lin CY; Hla T
    J Biol Chem; 2007 Mar; 282(12):9082-9. PubMed ID: 17237497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis.
    Sic H; Kraus H; Madl J; Flittner KA; von Münchow AL; Pieper K; Rizzi M; Kienzler AK; Ayata K; Rauer S; Kleuser B; Salzer U; Burger M; Zirlik K; Lougaris V; Plebani A; Römer W; Loeffler C; Scaramuzza S; Villa A; Noguchi E; Grimbacher B; Eibel H
    J Allergy Clin Immunol; 2014 Aug; 134(2):420-8. PubMed ID: 24679343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.
    Sawicka E; Dubois G; Jarai G; Edwards M; Thomas M; Nicholls A; Albert R; Newson C; Brinkmann V; Walker C
    J Immunol; 2005 Dec; 175(12):7973-80. PubMed ID: 16339533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.